Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program
AffiliationDepartment of Urology, University of Montreal Hospital Center, Montreal, Quebec, Canada
MetadataShow full item record
AbstractBACKGROUND: Radium-223 is approved by the US Food and Drug Administration and European Medicines Agency for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are currently no markers for selecting patients most likely to complete radium-223 treatment. PATIENTS AND METHODS: In this phase IIIb, international, single-arm study, patients received radium-223, 55 kBq/kg, every 4 weeks for </=6 cycleS Primary end points were safety and overall survivaL In post hoc analyses patients were grouped according to number of radium-223 injections received (1-4 or 5-6). Associations between baseline covariates and number of injections were investigated. RESULTS: Of 696 eligible patients, 473 (68%) had received 5 to 6 radium-223 injections and 223 (32%) 1 to 4 injectionS Patients with less pain (moderate-severe vS none-mild, odds ratio [OR], 0.41; P < .0001), lower Eastern Cooperative Oncol.ogy Group performance status (>/=2 vS 0-1, OR, 0.51; P = .0074), lower prostate-specific antigen level (>141 mug/L vS </=141 mug/L, OR, 0.40; P < .0001), and higher hemoglobin level (<10 g/dL vS >/=10 g/dL, OR, 0.50; P = .0206) were more likely to receive 5 to 6 than 1 to 4 injectionS Median overall survival was not reached and was 6.3 months (95% confidence interval, 5.4-7.4) in patients who had received 5 to 6 and 1 to 4 radium-223 injections, respectivelY Adverse events were less common in patients who received 5 to 6 than 1 to 4 injections; anemia was reported in 87 (18%) and 64 (29%) patients, respectively. CONCLUSION: Patients with less advanced mCRPC are more likely to receive 5 to 6 radium-223 injections and to achieve better overall survivaL Consideration of baseline and disease characteristics is recommended before initiation of radium-223 treatment.
CitationSaad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, et al. Disease characteristics and completion of treatment in patients with metastatic castration-resistant prostate cancer treated with radium-223 in an international early access program. Clin Genitourin Cancer. 2019.
JournalClinical Genitourinary Cancer
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
- Authors: Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM, Radium-223 International Early Access Program Investigators.
- Issue date: 2016 Sep
- Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
- Authors: Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F
- Issue date: 2019 Jan 7
- Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
- Authors: Sartor O, Heinrich D, Mariados N, Méndez Vidal MJ, Keizman D, Thellenberg Karlsson C, Peer A, Procopio G, Frank SJ, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, Trandafir L, Wagner V, Li R, Nordquist LT
- Issue date: 2019 Oct
- Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
- Authors: Uemura H, Uemura H, Nagamori S, Wakumoto Y, Kimura G, Kikukawa H, Yokomizo A, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Akagawa T, Matsubara N
- Issue date: 2019 May
- Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.
- Authors: Carles J, Castellano D, Méndez-Vidal MJ, Mellado B, Saez MI, González Del Alba A, Perez-Gracia JL, Jimenez J, Suárez C, Sepúlveda JM, Manneh R, Porras I, López C, Morales-Barrera R, Arranz JÁ
- Issue date: 2018 Dec